Publications

Research Articles in Peer-Reviewed Journals

  • Marchand, C., Bailly, C., McLean, MJ, Moroney, SE, Waring, MJ: The 2-amino group of guanine is absolutely required for specific binding of the anti-cancer antibiotic echinomycin to DNA.Nucleic Acids Research 20: 5601-5606, 1992.
  • Bailly, C., Marchand, C., Waring, MJ: New binding sites for antitumor antibiotics created by relocating the purine 2-amino group in DNA. Journal of the American Chemical Society 115:3784-3785, 1993.
  • Zhou, BW, Marchand, C., Asseline, U., Thuong, NT, Sun, JS, Garestier, T., Hélène, C.: Recognition of alternating oligopurine/oligopyrimidine tracts of DNA by oligonucleotides withbase-to-base linkages. Bioconjugate Chemistry 6: 516-523, 1995.
  • Bailly, C., Marchand, C., Nguyen, CH, Bisagni, E., Garestier, T., Hélène, C., Waring, MJ: Localized chemical reactivity in double-stranded DNA associated with the intercalative binding ofbenzo-e-pyridoindole and benzo-g-pyridoindole triple-helix-stabilizing ligands. European Journal of Biochemistry 232: 66-76, 1995.
  • Marchand, C., Bailly, C., Nguyen, CH, Bisagni, E, Garestier, T., Hélène, C., Waring MJ: Stabilization of triple helical DNA by a benzopyridoquinoxaline intercalator. Biochemistry 35:5022-5032, 1996.
  • Nguyen, CH, Marchand, C., Delage, S., Sun, JS, Garestier, T., Hélène, C., Bisagni, E.: Synthesis of 13H-benzo[6,7]- and 13H-benzo[4,5]indolo[3,2-c]-quinolines: a new series of potent specific ligands for triplex DNA. Journal of the American Chemical Society 120: 2501- 2507, 1998.
  • Marchand, C., Sun, JS, Bailly, C., Waring, MJ, Garestier, T., Hélène, C.: Optimization ofalternate-strand triple helix formation at the 5’CpG3’ and 5’GpC3’ junction steps. Biochemistry 37:13322-13329, 1998.
  • Baudoin, O., Marchand, C., Teulade-Fichou, MP, Vigneron, JP, Sun, JS, Garestier, T., Hélène, C., Lehn, JM: Stabilization of DNA triple helices by crescent-shaped dibenzophenanthrolines.Chemistry-A European Journal 4: 1504-1508, 1998.
  • Marchand, C., Zain, R., Sun, JS, Nguyen, CH, Bisagni, E., Garestier, T., Hélène, C.: Design of atriple-helix-specific cleaving reagent. Chemistry & Biology 6: 771-777, 1999.
  • Marchand, C., Nguyen, CH, Ward, B., Sun, JS, Bisagni, E., Garestier, T., Hélène, C.: A new family of sequence-specific DNA cleaving agents directed by triple-helical structures:Benzopyridoindole-EDTA conjugates. Chemistry-A European Journal 6: 1559-1563, 2000.
  • Jing, N., Marchand, C., Liu, J., Mitra, R., Hogan, ME, Pommier, Y.: Mechanism of inhibition ofHIV-1 integrase by G-tetrad forming oligonucleotides in vitro. The Journal of Biological Chemistry275: 21460-21467, 2000.
  • Pluymers, W., Pannecouque, C., Fikkert, V., Neamati, N., Marchand, C., Burke, TR Jr, Pommier, Y., Schools, D., De Clercq, E., Debyser, Z., Witvrouw, M.: Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. Molecular Pharmacology58: 641-648, 2000.
  • Pilon, A., Marchand, C., Kavlick, MF, Owen, J., Bajaj, K., Mitsuya, H., Pommier, Y.: Mutations in the HIV-1 integrase of patients receiving long-term dideoxynucleoside therapy do not confer resistance to AZT. AIDS Research and Human Retroviruses 16: 1417-1422, 2000.
  • Jing, N., Marchand, C., Guan, Y., Liu, J., Pallansch, LR, Lackman-Smith, C., De Clercq, E., Pommier, Y.: Structure-activity of inhibition of HIV-1 integrase and virus replication by G- quartet oligonucleotides. DNA and Cell Biology 20: 499-508, 2001.
  • Marchand, C., Pourquier, P., Laco, G., Jing, N., Pommier, Y.: Interaction of Topoisomerase I with G-quartet-forming and G-rich oligodeoxy- and oligoribonucleotides. The Journal of Biological Chemistry 277: 8906-8911, 2002.
  • Marchand, C., Zhang, X., Pais, GCG, Cowansage, K., Neamati, N., Burke, TR Jr, Pommier, Y.: Structural determinants for HIV-1 integrase inhibition by ß-diketo acids. The Journal of Biological Chemistry 277: 12596-12603, 2002.
  • Pais, GCG, Zhang, X., Marchand, C., Neamati, N., Cowansage, K., Svarovskaia, E., Pathak, VK, Tang, Y., Nicklaus, M., Pommier, Y., Burke TR Jr: Structure activity investigation of3-aryl-1,3-diketo containing compounds as HIV-1 integrase inhibitors. Journal of Medicinal Chemistry 45: 3184-3194, 2002.
  • Zhang, X., Pais, GCG, Svarovskaia, E., Marchand, C., Johnson, AA, Karki, RG, Nicklaus, M., Pathak, VK, Pommier, Y. Burke TR Jr: Azido-containing aryl beta-diketo acid HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry Letters 13: 1215-1219, 2003.
  • Marchand, C., Johnson, AA, Karki, RG, Pais, GCG, Zhang, X., Cowansage, K., Patel, TA, Nicklaus, M., Burke TR Jr, Pommier, Y.: Metal selectivity and resistance of the solubledouble-mutant integrase (F185K/C280S) for HIV-1 integrase inhibition by ß-diketo acids.Molecular Pharmacology 64: 600-609, 2003.
  • Krajewski, K., Long, YQ, Marchand, C., Pommier, Y., Roller, PP: Design and synthesis of dimeric HIV-1 integrase inhibitory peptides. Bioorganic & Medicinal Chemistry Letters 13:3203-3205, 2003.
  • Zhang, X., Marchand, C., Pommier, Y., Burke TR Jr: Design and synthesis of photoactivatable aryl diketo acid-containing HIV-1 integrase inhibitors as potential affinity probes. Bioorganic & Medicinal Chemistry Letters 14: 1205-1207, 2004.
  • Svarovskaia, E., Barr, R., Zhang, X., Pais, GCG, Marchand, C., Burke, TR Jr, Pommier, Y., Pathak, VK: Azido-containing diketo acid derivatives inhibit HIV-1 integrase in vivo and influence the frequency of deletions at the 2-LTR circle junctions. Journal of Virology 78: 3210-3222, 2004.
  • Krajewski, K., Marchand, C., Long, YQ, Pommier, Y., Roller PP: Synthesis and HIV-1 integrase inhibitory activity of dimeric and tetrameric analogs of indolicidin. Bioorganic & Medicinal Chemistry Letters 14: 5595-5598, 2004.
  • Di Santo, R., Costi, R., Artico, M., Ragno, R., Greco, G., Novellino, E., Marchand, C., Pommier, Y.: Design, synthesis and biological evaluation of heteroaryl diketohexenoic and diketobutanoic acids as HIV-1 integrase inhibitors endowed with antiretroviral activity. Farmaco 60: 409-417,2005.
  • Johnson, AA, Santos, W., Pais, GC, Marchand, C., Amin, R., Burke TR, Verdine, G., Pommier, Y.: Integration requires the donor DNA end (5’-C) interaction with glutamine 148 of the HIV-1integrase flexible loop. The Journal of Biological Chemistry 261: 461-467, 2006.
  • Marchand, C., Antony, S., Kohn, KW, Cushman, M., Ioanoviciu, A., Staker, BL, Burgin, AB, Stewart, L., Pommier, Y.: A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex. Molecular Cancer Therapeutics 5: 1-9, 2006.
  • Di Santo, R., Costi, R., Roux, A., Artico, M., Lavecchia, A., Marinelli, L., Novellino, E., Palmisano, L., Andreotti, M., Amici, R., Galluzzo, CM, Nencioni, L., Palarma, AT, Pommier, Y., Marchand, C*.: Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities and mechanism of action. Journal of Medicinal Chemistry 49:1939-1945, 2006.

    *Corresponding Author
  • Semenova, E., Johnson, A.A., Marchand, C., Davis, DA, Yarchoan, R., Pommier, Y.: Preferential inhibition of the magnesium-dependent strand transfer reaction of HIV-1 integrase by-hydroxytropolones. Molecular Pharmacology 69: 1454-1460, 2006.
  • Marchand, C., Krajewski, K., Lee, HF, Antony, S., Johnson, AA, Amin, R., Roller, P, Kvaratskhelia, M., Pommier, Y. Covalent binding of the natural antimicrobial peptide indolicidin to DNA abasic sites. Nucleic Acids Research 34: 5157-5165, 2006.
  • Bona, R., Andreotti, M., Buffa, V., Leone, P., Galluzzo, CM, Amici, R., Palmisano, L., Mancini, MG, Michelini, Z., Di Santo, R., Costi, R., Roux, A., Pommier, Y., Marchand. C.,
  • Vella, S., Cara, A.: Development of a Human Immunodeficiency Virus vector-based single- cycle assay for evaluation of anti-integrase compounds. Antimicrobial Agents and Chemotherapy 50:3407-3417, 2006.
  • Marchand, C., Johnson, AA, Patil, S., Costi, R., Di Santo, R., Burke, TR., Pommier, Y.: ProbingHIV-1 integrase inhibitor binding sites with position-specific integrase-DNA crosslinking assays.Molecular Pharmacology 71: 893-901, 2007.
  • Marchand, C., Antony, S., Stephen, AG, Thibaut, L., Agama, KK, Fisher, RJ, Pommier, Y.: Novel high-throughput electrochemiluminescent assay for identification of human tyrosyl- DNA phosphodiesterase (Tdp1) inhibitors and characterization of furamidine (NSC 305831) as an inhibitor of Tdp1. Nucleic Acids Research 35: 4474-4484, 2007.
  • Liao, C., Karki, RG, Marchand, C., Pommier, Y., Nicklaus, M.: Virtual screening application of a model of full-length HIV-1 integrase complexed with viral DNA. Bioorganic & Medicinal Chemistry Letters 17: 5361-5365, 2007.
  • Marchand, C., Beutler, JA, Warimu, A., budihas, S., Möllman, U., Heinisch, L., Mellors, JW, Le Grice, SF, Pommier, Y.: Madurahydroxylactones derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and RNase H. Antimicrobial Agents and Chemotherapy52: 361-364, 2008.
  • Zhao, XZ, Semenova, EA, Vu, C., Maddali, K., Marchand, C., Hughes, SH, Pommier, Y., Burke, TR: 2,3-Dihydro-6,7-dihydroxy-1H-isoindol-1-one-based HIV-1 integrase inhibitors. Journal of Medicinal Chemistry 51: 251-259, 2008.
  • Di Santo, R., Costi, R., Roux, A., Miele, G., Crucitti, GC, Iacovo, A., Rosi, F., Lavecchia, A., Marinelli, L., Di Giovanni, C., Novellino, E., Palmisano, L., Andreotti, M., Amici, R., Galluzzo, CM, Nencioni, L., Palamara, AT, Pommier, Y., Marchand, C*.: Novel quinolinonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, and biological activities. Journal of Medicinal Chemistry 51: 4744-50, 2008.
    • *Corresponding Author
  • Marinello, J., Marchand, C., Mott, BT, Bain, A., Thomas, CJ, Pommier, Y.: Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug- resistant integrase mutants. Biochemistry 47: 9345-54, 2008.
  • Marchand, C., Lea, W., Jadhav, A., Dexheimer, TS, Austin, CP, Inglese, J., Pommier, Y., Simeonov, A.: Identification of phosphotyrosine mimetic inhibitors of human tyrosyl-DNAphosphodiesterase I by a novel AlphaScreen high-throughput assay. Molecular Cancer Therapeutics 8: 242-250, 2009.
  • Zhao, XZ, Maddali, K., Vu, C., Marchand, C., Hughes, SH, Pommier, Y., Burke TR: Examination of halogen substituent effects on HIV-1 integrase inhibitors derived from 2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-ones and 4,5-dihydroxy-1H-isoindole-1,3(2H)-diones.Bioorganic & Medicinal Chemistry Letters 19: 2714-7, 2009.
  • Zhao, XZ, Maddali, K., Vu, C., Marchand, C., Hughes, SH, Pommier, Y., Burke, TR:Diketoacid-genre HIV-1 integrase inhibitors containing enantiomeric arylamide functionality.Bioorganic & Medicinal Chemistry 17: 5318-24, 2009.
  • Dexheimer, T., Gedya, LK, Stephen, AG, Weidlich, I., Antony, S., Marchand, C., Interthal, H., Nicklaus, M., Fisher, RJ, Njar, VC, Pommier, Y.: 4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesufonate) (NSC 88915) and Related Novel Steroid Derivatives as Tyrosyl- DNA Phosphodiesterase (Tdp1) Inhibitors. Journal of Medicinal Chemistry 52: 7122-31, 2009.
  • Weidlich IE, Dexheimer T, Marchand C, Antony S, Pommier Y, Nicklaus MC. Inhibitors of human tyrosyl-DNA phospodiesterase (hTdp1) developed by virtual screening using ligand- based pharmacophores. Bioorganic & Medicinal Chemistry 18: 182-9, 2010.
  • Michelini Z, Galluzzo CM, Negri DR, Leone P, Amici R, Bona R, Summa V, Di Santo R, Costi R, Pommier Y, Marchand C, Palmisano L, Vella S, Cara A. Evaluation of HIV-1 Integrase Inhibitors on Human Primary Macrophages Using a Luciferase-Based Single- Cycle Phenotypic Assay.Journal of virological methods 168: 272-6, 2010.
  • Métifiot M, Maddali K, Naumova A, Zhang X, Marchand C, Pommier Y. Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.Biochemistry 49: 3715-22, 2010.
  • Métifiot, M., Vandegraaff, N., Maddali, K., Naumova, A., Zhang, X., Rhodes, D., Marchand, C.Pommier, Y.: Molecular mechanism for elvitegravir activity against the integrase mutation Y143 associated with raltegravir resistance, AIDS 25: 1175-8, 2011.
  • Zhao XZ, Maddali K, Metifiot M, Smith SJ, Vu BC, Marchand C, Hughes SH, Pommier Y and Burke TR. Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors, Bioorganic & Medicinal Chemistry Letters 21, 2986-90, 2011
  • Métifiot, M., Johnson, B., Smith, S.J., Zhao, X.Z., Marchand, C., Burke, T.R., Hughes, SH, Pommier, Y.: MK-0536 inhibits HIV-1 integrases resistant to raltegravir, Antimicrobial agents and chemotherapy 11:5127-33, 2011.
  • Zhao, XZ., Maddali, K., Métifiot, M., Smith, S.J., Vu, C., Marchand, C., Hughes, SH, Pommier, Y., Burke, T.R.: Bicyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.Chemical Biology & Drug Design 79:157-165, 2012.
  • Nguyen, T.X., Morrell, A., Conda-Sheridan, M., Marchand, C., Agama, K., Bermingam, A., Stephen, A.G., Chergui, A., Naumova, A., Fisher, R., O'Keefe, B.R., Pommier, Y. and Cushman, M.: Synthesis and Biological Evaluation of the First Dual Tyrosyl-DNA Phosphodiesterase I(Tdp1)-Topoisomerase I (Top1) Inhibitors. The Journal of Medicinal Chemistry 55: 4457-78,2012.
  • Gao, R., Huang, S.N., Marchand, C. and Pommier, Y.: Biochemical characterization of human Tyrosyl DNA Phosphodiesterase 2 (TDP2/TTRAP): a Mg2+/Mn2+-dependent phosphodiesterase specific for the repair of topoisomerase cleavage complexes. The Journal of Biological Chemistry287: 30842-52, 2012.
  • Marchand C., Sirivolu V.R., Vernekar S.K., Naumova A., Chergui A., Renaud A., Stephen A.G., Chen F., Sham Y.Y., Pommier Y. and Wang Z. 5-Arylidenethioxothiazolidinones as Inhibitors ofTyrosyl-DNA Phosphodiesterase I. The Journal of Medicinal Chemistry 55: 8671-84, 2012.
  • Métifiot, M., Maddali, M., Johnson, B.C, Hare, S., Smith, S.J., Zhao, X.Z., Marchand, C., Burke, T.R.Jr., Hughes S.H., Cherepanov, P. and Pommier, Y. Activities, crystal structures and molecular dynamics of dihydro-1H-isoindole derivatives, inhibitors of HIV-1 integrase. ACS Chemical Biology, 8: 209-217, 2012.
  • Zhao XZ, Maddali K, Smith S.J., Métifiot M., Johnson BC, Marchand C, Hughes SH, Pommier Y, Burke TR Jr. 6,7-Dihydroxy-1-oxoisoindoline-4-sulfonamide-containing HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry Letters 22: 7309-7317, 2012.
  • Conda-Sheridan, M., Narasimha, R.P.V., Morrell, A., Cobb, B., Marchand, C.; Agama, K., Chergui, A., Renaud, A., Stephen, A., Pommier, Y. and Cushman, M. Synthesis and
  • Biological Evaluation of Indenoisoquinolines that Inhibit both Tyrosyl-DNA-
  • Phosphodiesterase I (Tdp1) and Topoisomerase I (Top1). The Journal of Medicinal Chemistry,56: 182-200, 2013.
  • Taliani S., Pugliesi I., Barresi E., Salerno S., Marchand C., Agama K., Simorini F., La Motta C., Marini A.M., Di Leva F. S., Marinelli L, Cosconati S., Novellino E., Pommier Y., Di Santo R., Da Settimo F. Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one: a suitable scaffold for the development ofnon-camptothecin Topoisomerase I (Top1) inhibitors. The Journal of Medicinal Chemistry, 56:7458-62, 2013.
  • Costi R, Métifiot M, Esposito F, Cuzzucoli Crucitti G, Pescatori L, Messore A, Scipione L, Tortorella S, Zinzula L, Novellino E, Pommier Y, Tramontano E, Marchand C*, Di Santo R.6-(1-Benzyl-1H-pyrrol-2-yl)-2,4-dioxo-5-hexenoic Acids as Dual Inhibitors of Recombinant HIV-1Integrase and Ribonuclease H, Synthesized by a Parallel Synthesis Approach. The Journal of Medicinal Chemistry, 56: 8588-8598, 2013.
    • *Corresponding Author
  • Zhao XZ, Smith SJ, Metifiot M, Johnson BC, Marchand C, Pommier Y, Hughes SH and Burke TR Jr. Bicyclic 1-Hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-Containing HIV-1 Integrase Inhibitors Having High Antiviral Potency Against Cells Harboring Raltegravir- Resistant Integrase Mutants. The Journal of Medicinal Chemistry, 57:1573-1582, 2014.
  • Beck DE, Agama K, Marchand C, Pommier Y, Cushman M. Synthesis and Biological Evaluation of New Carbohydrate-Substituted Indenoisoquinoline Topoisomerase I Inhibitors and Improved Syntheses of the Experimental Anticancer Agents Indotecan (LMP400) and Indimitecan (LMP776). The Journal of Medicinal Chemistry, 57:1495-1512, 2014.
  • Marchand C, Murai J, Sampada AS, Hongmao S, Ruili H, Yiping Z, Chergui A, Jiuping J, Doroshow JH, Jadhav A, Takeda S, Menghang X and Pommier Y. Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform. DNA Repair, 2014.
  • Costi R, Métifiot M, Suhman C, Crucitti GC, Maddali K, Pescatori L, Messore A, Scipione L, Tortorella S, Di Leva FS, Cosconati S, Marinelli L, Novellino E, Le Grice SFJ, Pommier Y,Marchand C*, and Di Santo R. 7-Amino-quinolinonyl Diketo Acid Derivatives as Dual Inhibitors of HIV Integrase and RNAse H Function of Reverse Transcriptase. The Journal of Medicinal Chemistry, 57: 3223-34,2014.
    • *Corresponding Author
  • Zhao XZ, Metifiot M, Smith SJ, Marchand C, Pommier Y, Hughes SH and Burke TR Jr. 4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-containing Compounds Having High Antiviral Potency Against Cells Harboring Raltegravir-Resistant Integrase Mutants. The Journal of Medicinal Chemistry, 2014.
  • Lv PC, Agama K, Marchand C, Pommier Y, Cushman M. Design, Synthesis, and Biological Evaluation of O-2-Modified Indenoisoquinolines as Dual Topoisomerase I (Top1)-Tyrosyl- DNA Phosphodiesterase I (TDP1) Inhibitors. The Journal of Medicinal Chemistry, 57: 4324- 4329, 2014.
  • Gao R, Schellenberg M, Marchand C, Abdelmalak M, Nitiss J, Williams S and Pommier Y. Proteasome degradation of topoisomerase II facilitates TDP2 processing of the 5’-Top2- DNA and -RNA adducts. The Journal of Biological Chemistry, 289: 17960-17969, 2014
  • Marchand C*, Huang SN, Dexheimer T, Lea W, Mott B, Chergui A, Naumova A, Rosenthal AS, Raj G, Gao R, Maloney DJ, Jadhav A, Jorgensen W, Simeonov A, Pommier Y. Biochemical assays for the discovery of TDP1 inhibitors. Molecular Cancer Therapeutics, 2014.
    • *Corresponding Author
  • Marchand C, Murai J, Shahane SA, Sun H, Huang R, Zhang Y, Chergui A, Ji J, Doroshow JH, Jadhav A, Takeda S, Xia M, Pommier Y. Identification of novel PARP inhibitors using acell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform. DNA Repair, 21:177-182, 2014
Review Articles:
  • Neamati, N., Marchand, C., Pommier, Y.: HIV-1 Integrase inhibitors: past, present and future.Advances in Pharmacology 49: 147-165, 2000.
  • Pommier, Y., Marchand, C., Neamati. N. Retroviral integrase inhibitors year 2000: update and perspectives. Antiviral Research 47: 139-148, 2000.
  • Marchand, C., Neamati, N., Pommier, Y.: In vitro HIV-1 integrase assays. Methods in Enzymology 340: 624-633, 2001.
  • Neamati, N., Marchand, C., Winslow, HE, Pommier, Y.: Human Immunodeficiency Virus type 1integrase-targeted inhibitor design. Antiretroviral Therapy 5: 87-103, 2001.
  • Johnson, AA, Marchand, C., Pommier, Y.: HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial. Current Topics in Medicinal Chemistry 4: 671-686, 2004.
  • Pommier, Y., Marchand, C. Interfacial inhibitors of the protein-nucleic acid interactions. Current Medicinal Chemistry – Anti Cancer Agents 5: 421-429, 2005.
  • Pommier, Y., Johnson, AA, Marchand, C. Integrase inhibitors to treat HIV/AIDS. Nature Reviews Drug Discovery 4: 236-248, 2005.
  • Pommier, Y., Ashutosh, RV, Sordet, O., Jobson, AG, Thibaut, L., Miao, Z., Seiler, J., Zhang, H.,Marchand, C., Agama, K., Redon. C.: Repair of topoisomerase I-mediated DNA damage. inProgress in Nucleic Acid Research and Molecular Biology. Moldave, K. (Ed). Academic Press/ Oxford Chapter 81, 175-221, 2006.
  • Marchand, C., Pommier, Y.: Interfacial inhibitors of human topoisomerase I. in Sequence Specific Binding Agents. Waring, M.J. (Ed). RSC Biomolecular Sciences/ Cambridge Chapter 2:29-43, 2006.
  • Marchand, C., Johnson, AA, Semenova, E., Pommier, Y.: Mechanisms and inhibition of HIV integration. Drug Discovery Today: Disease Mechanisms 3: 253-260, 2006.
  • Semenova, E., Johnson, AA, Marchand, C., Pommier, Y.: Integrase inhibitors. Current Opinions in HIV and AIDS 1: 380-387, 2006.
  • Marchand, C., Pommier, Y.: A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex. CCR Newsletter, Frontiers in Science 6: 1-5, 2007.
  • Semenova, AA, Marchand, C., Pommier, Y.: HIV-1 integrase inhibitors: update and perspectives. Advances in Pharmacology 56: 199-228, 2008.
  • Dexheimer, T., Antony, S., Marchand, C., Pommier, Y. Tyrosyl-DNA phosphodiesterase as a target for anticancer therapy. Anticancer Agents Medicinal Chemistry 8: 381-389, 2008.
  • Marchand, C., Maddali, K., Métifiot, M., Pommier, Y.: HIV-1 IN inhibitors: 2010 update and perspectives. Current Topics in Medicinal Chemistry 9: 1016-37, 2009.
  • Pommier, Y., Leo, E., Zhang, H., Marchand, C.: DNA topoisomerases and their anticancer and antibacterial inhibitors. Chemistry & Biology 17: 421-33, 2010.
  • Metifiot, M., Maddali, K., Marchand, C., Pommier, Y.: HIV integrase-resistance mutations: the bench and the bedside. Viruses 2: 1347-1366, 2010.
  • Liao C., Marchand, C., Burke, TR., Pommier, Y., Nicklaus, MC.: Authentic HIV-1 integrase inhibitors. Future Medicinal Chemistry 2: 1107-22, 2010.
  • Marchand, C. & Pommier, Y.: Topoisomerase Poisons: a Paradigm for Interfacial Inhibition in Topoisomerases and Cancer. Pommier, Y. (Ed), Springer – Cancer Research, New York, 2011.
  • Johnson, AA., Pommier, Y. & Marchand, C.: Insight into HIV-1 integrase–DNA interactions inHIV-1 Integrase. Neamati, N. (Ed), Wiley – Wiley Series in Drug Discovery and Development, Hoboken, New Jersey, 2011.
  • Huang, S.N., Pommier, Y. Marchand, C.: Tyrosyl-DNA Phosphodiesterase I (Tdp1) Inhibitors,Expert Opinion on Therapeutic Patents, 9: 1285-92, 2011
  • Pommier, Y. & Marchand, C.: Interfacial Inhibitors: Targeting Macromolecular Complexes,Nature Reviews Drug Discovery, 11: 25-36, 2012
  • Marchand, C*.: The Elvitegravir Quad Pill: The first Once-Daily Dual Target Anti-HIV Tablet,Expert Opinions on Investigational Drugs, 21: 901-4, 2012. *Editorial
  • Marchand, C*.: Dual Choice For Dual Target Anti-HIV Therapy, Journal of Clinical Research in HIV/ AIDS and Prevention, 1:1-2, 2012. *Editorial
  • Metifiot, M., Marchand, C., Pommier, Y.: HIV Integrase Inhibitors: 20-Year Landmark and Challenges. Adv Pharmacol. 67:75-105, 2013.
  • Dexheimer, T., Huang, S.N., Antony, S., Marchand, C., Pommier, Y. Tyrosyl-DNAphosphodiesterase as a target for anticancer therapy. Bentham eBook: Advances in Anticancer Agents in Medicinal Chemistry, Vol. 2, 444-471, 2013.
  • Pommier Y, Huang SN, Gao R, Das BB, Murai J, Marchand C. Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2). DNA Repair, 19:114-129, 2014.
Manuscripts In Preparation
  • Zhao XZ, Smith SJ, Metifiot M, Marchand C, Pommier Y, Hughes SH and Burke TR Jr. Novel HIV integrase inhibitors overcoming clinical resistance.


Christophe Marchand

Associate Scientist

 

  • : +1-301-435-2463
  • DEPARTMENTCenter for Cancer Research, National Cancer Institute
    National Institutes of Health
  • COUNTRY USA